Is it possible that the Trial design is a bit much and too complicated to simply know if Apabetalone avoids intensive care altogether? And Apabetalone is to be administered BID with meals. Do they serve meals in the IC? And the standard of care administered to patients includes monoclonal antibody treatment such as Remdesivir.

It would be nice to get feedback from the scientists on this Hub in this regard. 

https://clinicaltrials.gov/ct2/show/NCT04894266

Just saying ... Koo